Pub Date : 2024-12-01DOI: 10.1016/j.endien.2024.11.010
Patricia Enes Romero , María Güemes , Blanca Guijo , Gabriel Á. Martos-Moreno , Jesús Pozo Román , Jesús Argente
At present, the majority of patients with type 1 diabetes mellitus do not achieve the recommended glycemic control goals to reduce the risk of acute and chronic complications. Hybrid closed-loop systems or automated insulin infusion systems emerged as an opportunity to improve metabolic control, quality of life and reduce the psychosocial impact of type 1 diabetes. This article analyzes the evidence regarding their effectiveness and safety, the challenges they pose and best practices to optimize results when implemented in clinical practice.
{"title":"Automated insulin delivery systems in the treatment of diabetes: Benefits, challenges, and practical considerations in pediatric patients","authors":"Patricia Enes Romero , María Güemes , Blanca Guijo , Gabriel Á. Martos-Moreno , Jesús Pozo Román , Jesús Argente","doi":"10.1016/j.endien.2024.11.010","DOIUrl":"10.1016/j.endien.2024.11.010","url":null,"abstract":"<div><div>At present, the majority of patients with type 1 diabetes mellitus do not achieve the recommended glycemic control goals to reduce the risk of acute and chronic complications. Hybrid closed-loop systems or automated insulin infusion systems emerged as an opportunity to improve metabolic control, quality of life and reduce the psychosocial impact of type 1 diabetes. This article analyzes the evidence regarding their effectiveness and safety, the challenges they pose and best practices to optimize results when implemented in clinical practice.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 10","pages":"Pages 436-446"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.endien.2024.11.008
Roberto Sánchez Medina , Alejandro de Arriba Fernández , Ángela Gutiérrez Pérez , José Luis Alonso Bilbao
Introduction
The prevalence of diabetes mellitus (DM) has increased in low- and middle-income countries and in marginal areas of developed countries. In Spain, it grew by 3.42% from 1993 to 2020. In the Canary Islands, the increase was even greater.
Objectives
The main one was to evaluate the possible relationship of the income level with DM, different markers of metabolic control and the use of Primary Care services, in Las Palmas de Gran Canaria (LPGC). Secondary ones are to determine the prevalence of DM in the city of LPGC, to describe the sociodemographic characteristics, the use of Primary Care services of the population with DM, the level of registry of variables related to metabolic control and the main process indicators and intermediate results of the metabolic control in the population with DM in the city of LPGC.
Material and method
All patients with DM over 14 years of age, living in LPGC as of 12/31/22 were included. Data were collected from the electronic medical records of the Canarian Primary Care Service, the National Institute of Statistics and the National Tax Agency.
Results and conclusion
The overall prevalence of DM was 11.39%. The mean age of participants was 67.06 years (SD = 13.86), lower in men than in women. The groups with low or moderate income accounted for more than 40% of the prevalence each, while those with high income barely accounted for 10%. Higher income levels corresponded to lower use of health resources and registration of metabolic variables, while decreasing income levels were associated to higher prevalence of overweight/obesity, worse lipid and glycemic profiles and higher risk of diabetic foot. The middle-income group showed the highest prevalence of pathological/uncertain diabetic retinopathy, lower glomerular filtration and higher LDL levels.
在低收入和中等收入国家以及发达国家的边缘地区，糖尿病（DM）的患病率有所上升。在西班牙，从1993年到2020年增长了3.42%。在加那利群岛，这一增幅甚至更大。目的探讨拉斯帕尔马斯岛（Las Palmas de Gran Canaria， LPGC）居民收入水平与糖尿病、不同代谢控制指标和初级保健服务使用之间的关系。二是确定本市糖尿病患病率，描述本市糖尿病人群的社会人口学特征、初级保健服务使用情况、代谢控制相关变量登记水平以及本市糖尿病人群代谢控制的主要过程指标和中间结果。材料与方法纳入截至2012年12月31日、22日居住在LPGC的14岁以上DM患者。数据是从加那利初级保健服务处、国家统计局和国家税务局的电子病历中收集的。结果与结论糖尿病总患病率为11.39%。参与者的平均年龄为67.06岁（SD = 13.86），男性低于女性。低收入或中等收入群体占患病率的40%以上，而高收入群体仅占10%。收入水平越高，卫生资源的使用和代谢变量的登记就越少，而收入水平越低，超重/肥胖的患病率越高，血脂和血糖谱越差，糖尿病足的风险越高。中等收入组的病理性/不确定性糖尿病视网膜病变患病率最高，肾小球滤过率较低，LDL水平较高。
{"title":"Association between the economic situation and diabetes mellitus, metabolic control and the use of health services in a Spanish region","authors":"Roberto Sánchez Medina , Alejandro de Arriba Fernández , Ángela Gutiérrez Pérez , José Luis Alonso Bilbao","doi":"10.1016/j.endien.2024.11.008","DOIUrl":"10.1016/j.endien.2024.11.008","url":null,"abstract":"<div><h3>Introduction</h3><div>The prevalence of diabetes mellitus (DM) has increased in low- and middle-income countries and in marginal areas of developed countries<sub>.</sub> In Spain, it grew by 3.42% from 1993 to 2020. In the Canary Islands, the increase was even greater.</div></div><div><h3>Objectives</h3><div>The main one was to evaluate the possible relationship of the income level with DM, different markers of metabolic control and the use of Primary Care services, in Las Palmas de Gran Canaria (LPGC). Secondary ones are to determine the prevalence of DM in the city of LPGC, to describe the sociodemographic characteristics, the use of Primary Care services of the population with DM, the level of registry of variables related to metabolic control and the main process indicators and intermediate results of the metabolic control in the population with DM in the city of LPGC.</div></div><div><h3>Material and method</h3><div>All patients with DM over 14 years of age, living in LPGC as of 12/31/22 were included. Data were collected from the electronic medical records of the Canarian Primary Care Service, the National Institute of Statistics and the National Tax Agency.</div></div><div><h3>Results and conclusion</h3><div>The overall prevalence of DM was 11.39%. The mean age of participants was 67.06 years (SD<!--> <!-->=<!--> <!-->13.86), lower in men than in women. The groups with low or moderate income accounted for more than 40% of the prevalence each, while those with high income barely accounted for 10%. Higher income levels corresponded to lower use of health resources and registration of metabolic variables, while decreasing income levels were associated to higher prevalence of overweight/obesity, worse lipid and glycemic profiles and higher risk of diabetic foot. The middle-income group showed the highest prevalence of pathological/uncertain diabetic retinopathy, lower glomerular filtration and higher LDL levels.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 10","pages":"Pages 427-435"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.endien.2024.11.011
Natalia R. Iglesias , Romina Ceccomancini , María del Pilar Jaime , Ayla Gerk , Delfina Mendiola , Jorgelina Stegmann
Introduction
Self-perception of body image has been scarcely evaluated in people with Prader-Willi syndrome (PWS), who, in addition to intellectual disability, are often obese. Therefore, we explored whether people with PWS can accurately identify their true image and how this self-perception is impacted by their neuropsychological profile.
Methodology
This observational study included patients with PWS with regular attendance to transdisciplinary treatment at a center specialized in the management of rare diseases. All patients were evaluated with the Stunkard scale (including silhouettes ranging from extremely skinny to extremely obese) and the WISC-IV and WAIS-III questionnaires, specifically the perceptual reasoning index (PRI).
Results
Among the 21 participants, 62% misperceived their body image, most underestimating their body dimensions (actual BMI 28.0 ± 8.3 kg/m2 vs self-perceived BMI 23.2 ± 4.7 kg/m2, p = 0.03). While BMI differences between accurate and inaccurate body image perception were nonsignificant (accurate 26.6 ± 8.8 kg/m2 vs inaccurate 28.9 ± 8.1 kg/m2, p = 0.56), individuals with accurate perception showed both higher PRI scores (accurate 67.6 ± 8.2 vs inaccurate 60.2 ± 7.2, p = 0.043) and, to a lesser extent, intelligence quotients (IQ) (accurate 60.0 ± 4.9 vs inaccurate 55.0 ± 7.5, p = 0.079).
Conclusion
In this study, we identified distortion of body image perception as a very common finding among PWS patients, in most cases as underestimation, and influenced by the neuropsychological profile.
{"title":"Distortion of body image perception in the Prader-Willi syndrome: Relationship with the perceptual reasoning index","authors":"Natalia R. Iglesias , Romina Ceccomancini , María del Pilar Jaime , Ayla Gerk , Delfina Mendiola , Jorgelina Stegmann","doi":"10.1016/j.endien.2024.11.011","DOIUrl":"10.1016/j.endien.2024.11.011","url":null,"abstract":"<div><h3>Introduction</h3><div>Self-perception of body image has been scarcely evaluated in people with Prader-Willi syndrome (PWS), who, in addition to intellectual disability, are often obese. Therefore, we explored whether people with PWS can accurately identify their true image and how this self-perception is impacted by their neuropsychological profile.</div></div><div><h3>Methodology</h3><div>This observational study included patients with PWS with regular attendance to transdisciplinary treatment at a center specialized in the management of rare diseases. All patients were evaluated with the Stunkard scale (including silhouettes ranging from extremely skinny to extremely obese) and the WISC-IV and WAIS-III questionnaires, specifically the perceptual reasoning index (PRI).</div></div><div><h3>Results</h3><div>Among the 21 participants, 62% misperceived their body image, most underestimating their body dimensions (actual BMI 28.0<!--> <!-->±<!--> <!-->8.3<!--> <!-->kg/m<sup>2</sup> vs self-perceived BMI 23.2<!--> <!-->±<!--> <!-->4.7<!--> <!-->kg/m<sup>2</sup>, <em>p</em> <!-->=<!--> <!-->0.03). While BMI differences between accurate and inaccurate body image perception were nonsignificant (accurate 26.6<!--> <!-->±<!--> <!-->8.8<!--> <!-->kg/m<sup>2</sup> vs inaccurate 28.9<!--> <!-->±<!--> <!-->8.1<!--> <!-->kg/m<sup>2</sup>, <em>p</em> <!-->=<!--> <!-->0.56), individuals with accurate perception showed both higher PRI scores (accurate 67.6<!--> <!-->±<!--> <!-->8.2 vs inaccurate 60.2<!--> <!-->±<!--> <!-->7.2, <em>p</em> <!-->=<!--> <!-->0.043) and, to a lesser extent, intelligence quotients (IQ) (accurate 60.0<!--> <!-->±<!--> <!-->4.9 vs inaccurate 55.0<!--> <!-->±<!--> <!-->7.5, <em>p</em> <!-->=<!--> <!-->0.079).</div></div><div><h3>Conclusion</h3><div>In this study, we identified distortion of body image perception as a very common finding among PWS patients, in most cases as underestimation, and influenced by the neuropsychological profile.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 10","pages":"Pages 415-420"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.endien.2024.11.006
Emilio García García , Mercedes L. Llempén López , María Molina Mata , Rosa Cabello Laureano , Suset Dueñas Disotuar
{"title":"Early thyroid carcinoma in PTEN syndrome. Importance of immediate ultrasound screening","authors":"Emilio García García , Mercedes L. Llempén López , María Molina Mata , Rosa Cabello Laureano , Suset Dueñas Disotuar","doi":"10.1016/j.endien.2024.11.006","DOIUrl":"10.1016/j.endien.2024.11.006","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 9","pages":"Pages 407-408"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142645015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.endien.2024.11.007
Victor Perez de Arenaza Pozo, Jersy Cárdenas Salas, Clotilde Vázquez Martínez
{"title":"Potential of insulin deprescription adding a GLP-1 receptor agonist as a therapeutic strategy to improve the metabolic profiles of patients with type 2 diabetes mellitus","authors":"Victor Perez de Arenaza Pozo, Jersy Cárdenas Salas, Clotilde Vázquez Martínez","doi":"10.1016/j.endien.2024.11.007","DOIUrl":"10.1016/j.endien.2024.11.007","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 9","pages":"Pages 405-407"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.endien.2024.11.001
Carlos González-Contreras , Miquel Martorell , Natalia Ulloa , Carolina Ochoa-Rosales , Felipe Díaz-Toro , Fanny Petermann-Rocha , Carlos Celis-Morales , Marcelo Villagran , Lorena Mardones , on behalf of the ELHOC Group (Epidemiology of Lifestyle and Health Outcomes in Chile)
Introduction
Various polymorphisms in the beta-2 adrenergic receptor (ADRB2) gene have been associated with cardiometabolic risk factors, such as hypertension, dyslipidemia, type 2 diabetes mellitus and obesity contributing to the physiopathology of these chronic conditions. However, the association of the single nucleotide polymorphism (SNP) rs12654778 at the ADRB2 gene with metabolic changes has been poorly studied and there is no information on the Chilean adult population.
Objective
To investigate the association between the rs12654778 SNP at the ADRB2 gene with cardiometabolic risk markers in a Chilean adult population.
Methods
We conducted a cross-sectional study including 404 participants from the GENADIO study whom were genotyped for rs12654778 and categorized into GG, AG, and AA genotypes. Associations with cardiometabolic risk markers, such as blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, blood glucose and insulin were examined using multivariate regression analysis, while statistical models were adjusted for sociodemographic and lifestyle variables.
Results
Our findings indicate a significant association between the presence of the protective genotype (AA) of the rs12654778 polymorphism and lower low-density lipoprotein cholesterol levels corresponding to 8.75 mg/dL per each copy of the protective allele (maximally adjusted model). No significant associations were seen for the remaining variables.
Conclusion
The AA genotype of the rs12654778 SNP at the ADRB2 gene had a protective effect specifically against low-density lipoprotein cholesterol levels. This is the first study ever conducted in Chile on this SNP of ADRB2 and one of the few conducted worldwide to establish an association between the rs12654778 SNP at the ADRB2 gene and LDL cholesterol.
导言：β-2 肾上腺素能受体（ADRB2）基因中的多种多态性与高血压、血脂异常、2 型糖尿病和肥胖等心脏代谢风险因素有关，而这些因素是这些慢性疾病的生理病理因素。然而，关于 ADRB2 基因的单核苷酸多态性（SNP）rs12654778 与代谢变化之间的关系的研究却很少，而且也没有关于智利成年人群的信息。方法 我们进行了一项横断面研究，纳入了 404 名来自 GENADIO 研究的参与者，对他们进行了 rs12654778 基因分型，并将其分为 GG、AG 和 AA 基因型。研究人员使用多变量回归分析检验了这些基因与血压、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、甘油三酯、血糖和胰岛素等心脏代谢风险指标之间的关系，并根据社会人口学变量和生活方式变量对统计模型进行了调整。结果我们的研究结果表明，rs12654778 多态性的保护性基因型（AA）的存在与较低的低密度脂蛋白胆固醇水平之间存在显著的关联，每一个保护性等位基因拷贝对应 8.75 毫克/分升的低密度脂蛋白胆固醇水平（最大调整模型）。结论 ADRB2 基因中 rs12654778 SNP 的 AA 基因型对低密度脂蛋白胆固醇水平具有保护作用。这是智利首次对 ADRB2 基因的 SNP 进行研究，也是全球为数不多的在 ADRB2 基因的 rs12654778 SNP 与低密度脂蛋白胆固醇之间建立联系的研究之一。
{"title":"Association between the rs12654778 SNP of the β-2 adrenergic receptor and LDL cholesterol levels in the Chilean adult population","authors":"Carlos González-Contreras , Miquel Martorell , Natalia Ulloa , Carolina Ochoa-Rosales , Felipe Díaz-Toro , Fanny Petermann-Rocha , Carlos Celis-Morales , Marcelo Villagran , Lorena Mardones , on behalf of the ELHOC Group (Epidemiology of Lifestyle and Health Outcomes in Chile)","doi":"10.1016/j.endien.2024.11.001","DOIUrl":"10.1016/j.endien.2024.11.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Various polymorphisms in the beta-2 adrenergic receptor (<em>ADRB2</em>) gene have been associated with cardiometabolic risk factors, such as hypertension, dyslipidemia, type 2 diabetes mellitus and obesity contributing to the physiopathology of these chronic conditions. However, the association of the single nucleotide polymorphism (SNP) rs12654778 at the <em>ADRB2</em> gene with metabolic changes has been poorly studied and there is no information on the Chilean adult population.</div></div><div><h3>Objective</h3><div>To investigate the association between the rs12654778 SNP at the <em>ADRB2</em> gene with cardiometabolic risk markers in a Chilean adult population.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study including 404 participants from the GENADIO study whom were genotyped for rs12654778 and categorized into GG, AG, and AA genotypes. Associations with cardiometabolic risk markers, such as blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, blood glucose and insulin were examined using multivariate regression analysis, while statistical models were adjusted for sociodemographic and lifestyle variables.</div></div><div><h3>Results</h3><div>Our findings indicate a significant association between the presence of the protective genotype (AA) of the rs12654778 polymorphism and lower low-density lipoprotein cholesterol levels corresponding to 8.75<!--> <!-->mg/dL per each copy of the protective allele (maximally adjusted model). No significant associations were seen for the remaining variables.</div></div><div><h3>Conclusion</h3><div>The AA genotype of the rs12654778 SNP at the <em>ADRB2</em> gene had a protective effect specifically against low-density lipoprotein cholesterol levels. This is the first study ever conducted in Chile on this SNP of <em>ADRB2</em> and one of the few conducted worldwide to establish an association between the rs12654778 SNP at the <em>ADRB2</em> gene and LDL cholesterol.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 9","pages":"Pages 397-404"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.endien.2024.10.001
Jesús María de la Hera , Elías Delgado
{"title":"Heart failure in people with diabetes and obesity, can it be prevented?","authors":"Jesús María de la Hera , Elías Delgado","doi":"10.1016/j.endien.2024.10.001","DOIUrl":"10.1016/j.endien.2024.10.001","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 9","pages":"Pages 369-371"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.endien.2024.11.003
Javier Bodoque Cubas , José Fernández Sáez , Sergio Martínez Hervás , José Vicente Gil Boix , Juan José Salazar González , Raquel María Pallarés Gassulla , Sara Martínez Pérez , Marcel la Miret Llauradó , Iñaki Argüelles Jiménez , Santiago Tofé Povedano
Background and objective
The high incidence of thyroid nodular disease has raised concerns on the therapeutic management of benign thyroid nodules. The development of minimally invasive techniques is an alternative to surgery and has a low rate of complications. Our objective was to evaluate the safety and efficacy profile of percutaneous ethanol injections (PEI) with ethanol aspiration of symptomatic cystic and predominantly cystic thyroid nodules (cystic component > 50%) treated in the thyroid nodule high-resolution unit (TNHRU) of Hospital de Tortosa Verge de la Cinta Hospital, Tarragona, Spain.
Patients and methods
The present work is a prospective, observational and descriptive study of 32 patients (87.5% women, mean age of 43; SD, 12) evaluated at the TNHRU from August 2022 through December 2023. Demographic data such as age, sex, previous thyroid function, diagnostic method, initial nodular volume, nodular composition and nodular location were analyzed. Using ultrasounds, measurements of diameters and thyroid nodule volume were taken. We aspirated a total of 50% of the cystic content and injected between 2 mL and 5 mL of 99% ethanol (depending on cystic volume). After letting the ethanol act inside the nodule for 5 to 10 minutes, all the cystic content and the injected ethanol were aspirated. We performed an ultrasound follow-up at 1, 3 and 6 months, calculating the total volume and the volume reduction rate (VRR). The impact on health-related quality of life (HRQoL) was assessed using the ThyPRO-39es questionnaire, which was administered before and after the PEI treatment at the 6-month follow-up.
Results
The median volume reduction at the end of the 6-month follow-up was 0.23 mL (0.00–0.67), and the VRR, 98.57% (94.80–100.00). The difference between the initial volume and the mean volume at the 1-, 3-, and 6-month follow-ups was statistically significant, as was the VRR between the 1-month and the 3- and 6-month follow-ups. Six patients (18.80%) required 2 PEIs and only 2 patients (6.3%) required 3 PEIs. The overall quality of life, which was scored from 0 (good) to 4 (poor), significantly improved from 1.28; SD, 0.81 up to 0.19; SD, 0.40 (p < 0.001).
Conclusions
PEI is an effective alternative to treat cystic thyroid nodules resulting in an improved patients' HRQoL. It can be performed outpatiently with a low rate of complications, thus making it suitable for inclusion in the service portfolio of a HRTNU.
{"title":"Minimally invasive techniques for the management of benign thyroid nodules: Efficacy and impact on quality of life of percutaneous ethanol injection. Results from a high-resolution thyroid nodule unit","authors":"Javier Bodoque Cubas , José Fernández Sáez , Sergio Martínez Hervás , José Vicente Gil Boix , Juan José Salazar González , Raquel María Pallarés Gassulla , Sara Martínez Pérez , Marcel la Miret Llauradó , Iñaki Argüelles Jiménez , Santiago Tofé Povedano","doi":"10.1016/j.endien.2024.11.003","DOIUrl":"10.1016/j.endien.2024.11.003","url":null,"abstract":"<div><h3>Background and objective</h3><div>The high incidence of thyroid nodular disease has raised concerns on the therapeutic management of benign thyroid nodules. The development of minimally invasive techniques is an alternative to surgery and has a low rate of complications. Our objective was to evaluate the safety and efficacy profile of percutaneous ethanol injections (PEI) with ethanol aspiration of symptomatic cystic and predominantly cystic thyroid nodules (cystic component > 50%) treated in the thyroid nodule high-resolution unit (TNHRU) of Hospital de Tortosa Verge de la Cinta Hospital, Tarragona, Spain.</div></div><div><h3>Patients and methods</h3><div>The present work is a prospective, observational and descriptive study of 32 patients (87.5% women, mean age of 43; SD, 12) evaluated at the TNHRU from August 2022 through December 2023. Demographic data such as age, sex, previous thyroid function, diagnostic method, initial nodular volume, nodular composition and nodular location were analyzed. Using ultrasounds, measurements of diameters and thyroid nodule volume were taken. We aspirated a total of 50% of the cystic content and injected between 2 mL and 5 mL of 99% ethanol (depending on cystic volume). After letting the ethanol act inside the nodule for 5 to 10 minutes, all the cystic content and the injected ethanol were aspirated. We performed an ultrasound follow-up at 1, 3 and 6 months, calculating the total volume and the volume reduction rate (VRR). The impact on health-related quality of life (HRQoL) was assessed using the ThyPRO-39es questionnaire, which was administered before and after the PEI treatment at the 6-month follow-up.</div></div><div><h3>Results</h3><div>The median volume reduction at the end of the 6-month follow-up was 0.23 mL (0.00–0.67), and the VRR, 98.57% (94.80–100.00). The difference between the initial volume and the mean volume at the 1-, 3-, and 6-month follow-ups was statistically significant, as was the VRR between the 1-month and the 3- and 6-month follow-ups. Six patients (18.80%) required 2 PEIs and only 2 patients (6.3%) required 3 PEIs. The overall quality of life, which was scored from 0 (good) to 4 (poor), significantly improved from 1.28; SD, 0.81 up to 0.19; SD, 0.40 (p < 0.001).</div></div><div><h3>Conclusions</h3><div>PEI is an effective alternative to treat cystic thyroid nodules resulting in an improved patients' HRQoL. It can be performed outpatiently with a low rate of complications, thus making it suitable for inclusion in the service portfolio of a HRTNU.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 9","pages":"Pages 380-389"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142645017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.endien.2024.11.002
Liang Cao , Xiangrong Pan , Ying Li , Wei Jia , Jiayang Huang , Jian Liu
Objectives
To investigate the serum levels of miR-409-3p in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD) and its effect on high glucose (HG)-induced myocardial cell injury.
Methods
A total of 250 patients with T2DM admitted to our hospital from April 2020 through April 2022 were enrolled as the study subjects, and then grouped into T2DM + CHD (group #1) and T2DM (group #2). Real-time quantitative PCR (RT-qPCR) was used to measure the levels of serum miR-409-3p. The clinical performance of miR-409-3p was evaluated. The human cardiomyocyte AC16 cells were cultured in vitro and treated with HG. MTT assay and flow cytometry were performed to detect cell viability and apoptosis, respectively. Bioinformatic analyses were performed to explore the potential mechanism of miR-409-3p in T2DM complicated with CHD.
Results
The expression level of miR-409-3p was increased in the T2DM + CHD group and had a relative high diagnostic value for distinguishing patients with T2DM + CHD from patients with T2DM alone. Correlation analysis showed that serum miR-409-3p was positively associated with the Gensini score and adverse cardiovascular events; miR-409-3p knockdown alleviated HG-induced AC16 cell damage and reduced cell apoptosis. CREB1, BCL2, and SMAD2 were the top 3 hub genes of miR-409-3p.
Conclusion
Serum miR-409-3p may serve as a potential diagnostic and prognostic biomarker for predicting T2DM complicated with CHD and forecast adverse events. Targeting miR-409-3p may be a novel therapeutic strategy to intervene in the development of T2DM + CHD.
{"title":"Predictive value of circulating miR-409-3p for major adverse cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease","authors":"Liang Cao , Xiangrong Pan , Ying Li , Wei Jia , Jiayang Huang , Jian Liu","doi":"10.1016/j.endien.2024.11.002","DOIUrl":"10.1016/j.endien.2024.11.002","url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate the serum levels of miR-409-3p in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD) and its effect on high glucose (HG)-induced myocardial cell injury.</div></div><div><h3>Methods</h3><div>A total of 250 patients with T2DM admitted to our hospital from April 2020 through April 2022 were enrolled as the study subjects, and then grouped into T2DM<!--> <!-->+<!--> <!-->CHD (group #1) and T2DM (group #2). Real-time quantitative PCR (RT-qPCR) was used to measure the levels of serum miR-409-3p. The clinical performance of miR-409-3p was evaluated. The human cardiomyocyte AC16 cells were cultured in vitro and treated with HG. MTT assay and flow cytometry were performed to detect cell viability and apoptosis, respectively. Bioinformatic analyses were performed to explore the potential mechanism of miR-409-3p in T2DM complicated with CHD.</div></div><div><h3>Results</h3><div>The expression level of miR-409-3p was increased in the T2DM<!--> <!-->+<!--> <!-->CHD group and had a relative high diagnostic value for distinguishing patients with T2DM<!--> <!-->+<!--> <!-->CHD from patients with T2DM alone. Correlation analysis showed that serum miR-409-3p was positively associated with the Gensini score and adverse cardiovascular events; miR-409-3p knockdown alleviated HG-induced AC16 cell damage and reduced cell apoptosis. CREB1, BCL2, and SMAD2 were the top 3 hub genes of miR-409-3p.</div></div><div><h3>Conclusion</h3><div>Serum miR-409-3p may serve as a potential diagnostic and prognostic biomarker for predicting T2DM complicated with CHD and forecast adverse events. Targeting miR-409-3p may be a novel therapeutic strategy to intervene in the development of T2DM<!--> <!-->+<!--> <!-->CHD.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 9","pages":"Pages 372-379"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号